Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
For decades, the rare disease Hereditary Angioedema (HAE) overwhelmed Melissa’s days. But today she’s making up for lost time…
Makiko Matsuyama, president of Japan’s Hereditary Angioedema (HAE) patient association, discusses the danger of undiagnosed H…
Dr. Konrad Bork encourages the next generation of physicians to listen to their patients and stay curious. He’s been research…
We’re counting down to a special event that invites kids with bleeding disorders to learn and compete together.
Who’s a good dog? Companion animals show up in a special way for those managing rare and chronic conditions.
We stand with the Kankakee community in support of cleanup and rebuilding efforts.
We’re investing significantly in the United States to expand our ability to manufacture plasma–based medicines. Here are five…
More than half of those surveyed said they provided unpaid care to a family member or friend who has a rare disease.
How do you lead through change and stay focused on progress? In honor of International Women’s Day, we interviewed leaders to…
Americas
Asia Pacific
Middle East
Europe
